Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The increased focus of Chinese companies on innovative drugs led to the approval of 30 medicines discovered in China in 2023, accounting for 37% of new drugs approved in China overall. Here, with the aim of illuminating the evolution in pharmaceutical R&D in China in recent years, we overview the current pipeline of domestic innovative drug candidates and compare it with our previous analysis from 2021 (Nat. Rev. Drug Discov.21, 553–554; 2022). For details of the dataset and analysis, see Supplementary Box 1.
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41573-024-00120-5
Acknowledgements
The authors gratefully acknowledge the Pharmcube team for their contribution to the work. This work was funded by National Natural Science Foundation of China (72374119) and Beijing Nova Program.
